Denmark · Delayed Price · Currency is DKK Genmab Earnings Call Transcripts
Fiscal Year 2026
-
Three late-stage assets are set for pivotal readouts in 2026, with strong commercial and financial prospects driven by robust clinical data and expansion into broader patient populations. Direct commercialization in key markets and ongoing R&D are expected to sustain growth beyond the loss of major royalties.
-
Strong financial performance and late-stage pipeline progress set the stage for major 2026 milestones, including pivotal trial readouts for EPKINLY, Rina-S, and petosemtamab. Commercial infrastructure is ready for launches in 2027, with each program targeting multi-billion dollar opportunities.
-
Strong recurring revenue growth and disciplined OpEx management are expected to continue through 2027, with EPKINLY driving near-term growth and new launches for Rina-S and Petosemtamab anticipated to contribute meaningfully from 2028. Peak sales targets for late-stage assets are set to offset potential royalty declines, while deleveraging and profitability remain key priorities.
-
A diversified late-stage pipeline and disciplined capital allocation position the business for sustainable growth, with 2026 expected to deliver pivotal data readouts for Epkinly, Rina-S, and petosemtamab. Integration of Merus assets and operational efficiencies support multiple high-impact launches in 2027.
Fiscal Year 2025
-
Revenue grew 19% to $3.7B in 2025, with proprietary medicines up 54% and operating profit at $1.26B. EPKINLY and TIVDAK drove strong sales and regulatory milestones, while the Merus acquisition expanded the late-stage pipeline. 2026 guidance targets 14% revenue growth and continued investment in launches.
-
Transformative clinical data for epcoritamab-based regimens in lymphoma led to regulatory approvals and strong momentum. Strategic acquisitions and targeted R&D investments are accelerating the shift to a fully integrated, growth-oriented business, with multiple pivotal data readouts and product launches anticipated by 2027.
-
Late-stage oncology programs are advancing, with key data readouts and launches expected in 2026–2027. Epkinly, RENA-S, and PETO are positioned for significant growth, supported by strong financials and disciplined capital allocation.
-
Late-stage assets Epkinly, Rina-S, Acasunlimab, and Petosemtamab are prioritized, with strong clinical data supporting their advancement. 2026 will be an investment year, targeting major launches in 2027 and significant EBITDA growth by 2029, driven by robust sales projections for Peto and Rina-S.
-
Revenue grew 21% and operating profit 52% year-over-year, driven by strong recurring revenue and product sales. Late-stage pipeline advanced, with Epkinly and TIVDAK sales up 54% and a proposed Merus acquisition to diversify the portfolio. Guidance for double-digit growth remains on track.
-
The acquisition of Merus N.V. for $8 billion brings PETO, a breakthrough bispecific antibody for head and neck cancer, into the late-stage pipeline, supporting a shift to a fully integrated biotech model. PETO is expected to launch in 2027, with multi-billion dollar sales potential and significant portfolio synergies.
-
Strong 2025 performance is driven by late-stage oncology assets EPKINLY and Rina-S, with both showing compelling clinical data and upgraded peak sales targets. EPKINLY's phase III readouts and Rina-S's expansion in gynecological cancers are key near-term catalysts.
-
The conference highlighted robust late-stage clinical progress for EPKINLY and RINASCE, with strong commercial momentum and plans for global expansion. Strategic capital allocation, AI integration, and a focus on innovation and partnerships position the company for sustained growth.
-
Revenue grew 19% and operating profit 56% in H1 2025, driven by strong sales of EPKINLY and Tivdak, robust royalties, and disciplined investment in late-stage programs. Upgraded guidance reflects continued momentum, with key clinical milestones achieved for epcoritamab and Rina-S.
-
Strong Q1 results and ASCO data highlight robust growth, with Epkinly and Rina-S leading a diverse pipeline. Multiple late-stage trials and new indications support upgraded sales guidance, while risk management and capital allocation remain key priorities.
-
Significant progress was highlighted across late-stage oncology assets, with Rina-S and EPKINLY advancing toward pivotal studies and regulatory filings. Strong financials support ongoing R&D and business development, with key data updates expected by year-end.
-
Rinatabart Sesutecan showed robust, durable responses in heavily pretreated ovarian and endometrial cancers, with efficacy across all folate receptor alpha expression levels and a favorable safety profile. Multiple pivotal trials are underway or planned, with commercial launch in ovarian cancer targeted for 2027 and peak sales expected to exceed $2 billion.
-
Revenue grew 19% year-over-year, driven by EPKINLY and Tivdak, with operating profit up 62%. Strong recurring revenues, robust pipeline progress, and new regulatory approvals support a positive outlook, with 2025 guidance reaffirmed and a share buyback underway.
-
Discontinuation of HexaBody-CD38 development was driven by market and portfolio priorities, but strong clinical data validate the HexaBody platform for future assets. Focus remains on advancing late-stage programs EPKINLY, Rina-S, and Acasunlimab, with robust financial guidance and active M&A strategy.
-
Capital allocation is focused on late-stage R&D, with significant investment in EPKINLY, Rina-S, and Acasunlimab. Commercial expansion in Europe and Japan is underway, leveraging TIVDAK rights and preparing for Rina-S launches. Multiple phase 3 trials and new pipeline assets are advancing, with strong financial growth and a robust royalty business supporting future innovation.
-
The conference highlighted a robust late-stage pipeline, with accelerated development of Rina-S and Acasunlimab, and a strategic shift toward greater asset ownership and disciplined investment. Partnerships and external innovation remain key, with 2025 investment focused on phase II/III trials.
Fiscal Year 2024
-
Achieved 31% revenue growth and 26% operating profit growth in 2024, driven by strong sales of EPKINLY, Tivdak, and DARZALEX. Guidance for 2025 projects continued double-digit growth, with major investments in late-stage R&D and a new $370 million share buyback.
-
Significant regulatory approvals and pipeline expansion were achieved, with robust clinical data for Rina-S and Epkinly supporting durable responses and manageable safety. Key late-stage trials are ongoing, and major data readouts and regulatory decisions are anticipated in 2025.
-
Focused on antibody-based oncology, the company advances seven phase 3 trials across key assets, with Epkinly, Rina-S, and Axonimab driving future growth. Strategic investments in commercialization and disciplined capital allocation support expansion, while a robust royalty portfolio underpins long-term prospects.
-
Epkinly continues to outperform in key markets, with broad expansion plans and multiple phase III trials underway. Acasunlimab advances to phase III with full ownership, while the ProfoundBio acquisition strengthens the ADC pipeline. Financial discipline and program prioritization remain central for 2025.
-
Strong revenue and profit growth driven by EPKINLY, Tivdak, and Darzalex royalties, with recurring revenues now 92% of total. Strategic pipeline prioritization advanced late-stage assets and discontinued less promising programs, while guidance for 2024 was raised.
-
The business is evolving into an integrated innovation leader, accelerating late-stage development and commercialization, especially for ADCs like Rina-S and immune activators. Key milestones ahead include pivotal trial starts, broadening indications, and major data releases for Rina-S, acasunlimab, and GEN3014.
-
ProfoundBio acquisition and strong H1 revenue growth drove raised full-year guidance. Key products like DARZALEX, Kesimpta, Epkinly, and Tivdak delivered robust performance, while two wholly owned assets advance to late-stage development.
-
The event highlighted robust commercial growth, pipeline advancements, and strategic integration of ProfoundBio, with key data updates and registration trials for Rina-S and GEN1046 expected in the second half of 2024. EPKINLY and TIVDAK continue to drive revenue, while DARZALEX maintains a strong market position.
-
Promising clinical data were presented for tisotumab vedotin in head and neck cancer, epcoritamab in follicular lymphoma, and acasunlimab plus pembrolizumab in NSCLC, with strong efficacy and manageable safety. Phase III trials are set to begin, and regulatory submissions are underway.